CL2020001875A1 - Inhibidores de pi4kiiiß - Google Patents

Inhibidores de pi4kiiiß

Info

Publication number
CL2020001875A1
CL2020001875A1 CL2020001875A CL2020001875A CL2020001875A1 CL 2020001875 A1 CL2020001875 A1 CL 2020001875A1 CL 2020001875 A CL2020001875 A CL 2020001875A CL 2020001875 A CL2020001875 A CL 2020001875A CL 2020001875 A1 CL2020001875 A1 CL 2020001875A1
Authority
CL
Chile
Prior art keywords
inhibitors
pi4kiiiß
compounds
viral
exacerbated
Prior art date
Application number
CL2020001875A
Other languages
English (en)
Inventor
Nicholas Paul Barton
Sophie Marie Bertrand
Kenneth Down
Matthew Gray
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800734.4A external-priority patent/GB201800734D0/en
Priority claimed from GBGB1817616.4A external-priority patent/GB201817616D0/en
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2020001875A1 publication Critical patent/CL2020001875A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (I) que son inhibidores de la actividad quinasa, a formulaciones farmacéuticas que contienen dichos compuestos y a sus usos en el tratamiento y prevención de infecciones y trastornos virales causados o exacerbados por la infección viral. en donde R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y y Z se definen en la presente.
CL2020001875A 2018-01-17 2020-07-15 Inhibidores de pi4kiiiß CL2020001875A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1800734.4A GB201800734D0 (en) 2018-01-17 2018-01-17 Novel compounds
GBGB1817616.4A GB201817616D0 (en) 2018-10-29 2018-10-29 Novel compounds

Publications (1)

Publication Number Publication Date
CL2020001875A1 true CL2020001875A1 (es) 2021-02-12

Family

ID=65033598

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001875A CL2020001875A1 (es) 2018-01-17 2020-07-15 Inhibidores de pi4kiiiß

Country Status (19)

Country Link
US (2) US11649238B2 (es)
EP (1) EP3740489A1 (es)
JP (2) JP7133023B2 (es)
KR (1) KR102523513B1 (es)
CN (2) CN111868063B (es)
AR (1) AR114082A1 (es)
AU (1) AU2019208416B2 (es)
BR (1) BR112020014431A2 (es)
CA (1) CA3088347A1 (es)
CL (1) CL2020001875A1 (es)
CO (1) CO2020008887A2 (es)
IL (1) IL276013B2 (es)
MA (1) MA51611A (es)
MX (1) MX2020007521A (es)
PH (1) PH12020551034A1 (es)
SG (1) SG11202006453SA (es)
TW (1) TWI795510B (es)
UY (1) UY38051A (es)
WO (1) WO2019141694A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7133023B2 (ja) * 2018-01-17 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｐｉ４ｋｉｉｉベータ阻害剤
US20240066037A1 (en) 2020-03-26 2024-02-29 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
JP2024501118A (ja) 2020-11-20 2024-01-11 ２６９２３７２ オンタリオ，インク． Ｋｒａｓ修飾のための方法および組成物
US20240018153A1 (en) 2020-11-20 2024-01-18 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
LU85034A1 (fr) 1982-10-08 1985-06-19 Glaxo Group Ltd Dispositifs en vue d'administrer des medicaments a des patients
BE905189A (fr) 1985-07-30 1987-01-29 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients.
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
ES2179192T3 (es) 1995-04-14 2003-01-16 Smithkline Beecham Corp Inhibidor dosificador para albuterol.
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
PL354675A1 (en) 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
MXPA05002571A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
US8113199B2 (en) 2004-02-16 2012-02-14 Glaxo Group Limited Counter for use with a medicament dispenser
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
MX354676B (es) * 2011-08-19 2018-03-15 Glaxo Group Ltd Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
US8633198B1 (en) 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
US9714248B2 (en) 2012-12-20 2017-07-25 Ucb Pharma S.A. Therapeutically active pyrazolo-pyrimidine derivatives
WO2014113942A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US9580431B2 (en) * 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP6509238B2 (ja) 2014-01-22 2019-05-08 キュロヴィル・アクチボラグ 治療に有用なピラゾロ［１，５−ａ］ピリミジン−７−アミン誘導体
GB201410816D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
CA2989722C (en) * 2015-06-24 2023-09-19 Jacob Westman Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
GB201517263D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
CN116082366A (zh) 2017-03-31 2023-05-09 巴斯夫欧洲公司 用于防除动物害虫的嘧啶鎓化合物及其混合物
CL2020000127A1 (es) 2017-07-13 2020-04-24 Michael David Forrest Moduladores terapéuticos del modo inverso de la atp sintasa.
JP7133023B2 (ja) * 2018-01-17 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｐｉ４ｋｉｉｉベータ阻害剤
MX2020007535A (es) 2018-01-17 2020-12-07 Aurigene Discovery Tech Ltd Compuestos de alquinileno sustituidos como agentes anticancerigenos.
JP7447110B2 (ja) 2018-10-29 2024-03-11 マイオカーディア，インク テトラヒドロピラン（ｔｈｐ）－置換二環式－ピリミジンジオン化合物
BR112021006860A2 (pt) 2018-10-29 2021-08-10 Nippon Soda Co., Ltd. composto, agentes de controle de pragas, de controle de ectoparasitas, expulsor de endoparasitas ou de controle de endoparasitas, de tratamento de sementes ou de tratamento de órgãos de propagação vegetativos, de tratamento de solo e de isca, inseticida ou acaricida, composição agroquímica granular, e, promotor de crescimento de plantas

Also Published As

Publication number Publication date
PH12020551034A1 (en) 2021-09-06
CA3088347A1 (en) 2019-07-25
JP2021510711A (ja) 2021-04-30
KR20200109343A (ko) 2020-09-22
EP3740489A1 (en) 2020-11-25
JP7133023B2 (ja) 2022-09-07
CN117069728A (zh) 2023-11-17
CO2020008887A2 (es) 2020-07-31
TW201940173A (zh) 2019-10-16
MX2020007521A (es) 2022-12-05
US11649238B2 (en) 2023-05-16
US20230124394A1 (en) 2023-04-20
MA51611A (fr) 2021-04-21
IL276013B2 (en) 2024-03-01
IL276013B1 (en) 2023-11-01
JP7338017B2 (ja) 2023-09-04
KR102523513B1 (ko) 2023-04-18
UY38051A (es) 2019-08-30
US20210387988A1 (en) 2021-12-16
BR112020014431A2 (pt) 2020-12-01
JP2022172223A (ja) 2022-11-15
CN111868063B (zh) 2023-08-01
TWI795510B (zh) 2023-03-11
RU2020123034A (ru) 2022-02-17
SG11202006453SA (en) 2020-08-28
AU2019208416A1 (en) 2020-07-23
AR114082A1 (es) 2020-07-22
WO2019141694A1 (en) 2019-07-25
IL276013A (en) 2020-08-31
AU2019208416B2 (en) 2021-07-29
CN111868063A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
CL2020001875A1 (es) Inhibidores de pi4kiiiß
CL2018002516A1 (es) Inhibidores de mcl-1 indólicos sustituidos.
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
CL2017002709A1 (es) Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
BR112017002942A2 (pt) compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53
CL2020001749A1 (es) Derivado de amino-metil piperidina como inhibidor de quinasa.
CL2017001001A1 (es) Derivados de carbazaol
DOP2021000111A (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
MX2022006466A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
EA201791348A1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
CO2022014876A2 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CO7131369A2 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
PE20220400A1 (es) Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio
ECSP19026702A (es) Compuestos novedosos para el tratamiento de enfermedades parasitarias
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CL2017002229A1 (es) Inhibidores de bace1.
EA202091341A1 (ru) Пиразолопиримидины, обладающие активностью в отношении респираторно-синцитиального вируса (rsv)